BMC Cancer

Table 1 Clinical characteristics between a screening and a validation set of patients

From: microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer

Characteristic	Screening set (n = 30)					Validation set (n = 34)
	KRAS/BRAF wt(n = 15)		BRAF mt(n = 15)			KRAS/BRAF wt(n = 30)		BRAF mt(n = 4)
	n	%	n	%	P	n	%	n	%	P
Age
Median	66		68		0.80^a	67		77		0.054^a
Range	39–82		27–87			50–92		69–87
Gender
Men	11	73	11	73	1.00^b	17	57	2	50	1.00^b
Women	4	27	4	27		13	43	2	50
Stage
I	0	0	0	0	0.55^c	1	3.3	0	0	0.62^c
II	3	20	4	27		0	0	0	0
III	6	40	3	20		24	80	4	100
IV	6	40	7	46		5	16	0	0
Unknown	0	0	1	7		0	0	0	0
Histology
Pap	0	0	0	0	0.32^c	0	0	0	0	0.86^c
Tub	13	86	8	53		26	87	4	100
Por	1	7	2	13		1	3	0	0
Muc	1	7	3	20		1	3	0	0
Sig	0	0	1	7		0	0	0	0
Unknown	0	0	1	7		2	7	0	0
Location
Proximal	3	20	8	53	0.06^b	9	30	3	75	0.12^b
Distal	12	80	6	40		21	70	1	25
Unknown	0	0	1	7		0	0	0	0

^aMann-Whitney U test
^bFisher’s exact test
^cchi-square tests were used for the comparison of categorical variables between KRAS/BRAF-wild-type and BRAF-mutant cancers among the screening or the validation set

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com